Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid
Case 1: A 65-year-old man with novel coronavirus infection (COVID-19) complicated with acute respiratory failure. On admission, the patient was started on favipiravir and corticosteroid. However, due to a lack of significant improvement, he was introduced to mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Although iliopsoas hematoma occurred as a complication, the patient recovered. Case 2: A 49-year-old man with COVID-19 had been started on favipiravir and corticosteroid. Due to progressive respiratory failure, the patient underwent mechanical ventilation and ECMO. The patient recovered without complications. We successfully treated these severe cases with a multimodal combination of pharmacological and non-pharmacological supportive therapy.
Media Type: |
Electronic Article |
---|
Year of Publication: |
2021 |
---|
Contained In: |
Internal medicine (Tokyo, Japan) - Vol. 60, No. 1 (2021), p. 123-130 |
---|
Language: |
English |
---|
Urls: |
---|
Notes: |
Date Completed 12.01.2021 Date Revised 12.01.2021 published: Print-Electronic Citation Status MEDLINE Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine |
---|
Physical Description: |
Online-Ressource |
---|
doi: |
10.2169/internalmedicine.5475-20 |
---|---|
PMID: |
33390469 |
PPN (Catalogue-ID): |
NLM32056195X |
---|
LEADER | 04236nma a2201021 c 4500 | ||
---|---|---|---|
001 | NLM32056195X | ||
003 | DE-601 | ||
005 | 20210113215514.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210104s2021 000 0 eng d | ||
024 | 7 | |a 10.2169/internalmedicine.5475-20 |2 doi | |
028 | 5 | 2 | |a pubmed21n1109.xml |
035 | |a (DE-599)NLM33390469 | ||
040 | |b ger |c GBVCP | ||
041 | 0 | |a eng | |
100 | 1 | |a Shinoda, Masahiro | |
245 | 1 | 0 | |a Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid |h Elektronische Ressource |
300 | |a Online-Ressource | ||
500 | |a Date Completed 12.01.2021 | ||
500 | |a Date Revised 12.01.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
500 | |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine | ||
520 | |a Case 1: A 65-year-old man with novel coronavirus infection (COVID-19) complicated with acute respiratory failure. On admission, the patient was started on favipiravir and corticosteroid. However, due to a lack of significant improvement, he was introduced to mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Although iliopsoas hematoma occurred as a complication, the patient recovered. Case 2: A 49-year-old man with COVID-19 had been started on favipiravir and corticosteroid. Due to progressive respiratory failure, the patient underwent mechanical ventilation and ECMO. The patient recovered without complications. We successfully treated these severe cases with a multimodal combination of pharmacological and non-pharmacological supportive therapy | ||
611 | 2 | 7 | |a Case Reports |2 gnd |
611 | 2 | 7 | |a Journal Article |2 gnd |
653 | 2 | |a Adrenal Cortex Hormones |6 D000305 |a *therapeutic use |6 Q000627 | |
653 | 2 | |a Aged |6 D000368 | |
653 | 2 | |a Amides |6 D000577 |a *therapeutic use |6 Q000627 | |
653 | 2 | |a Antiviral Agents |6 D000998 |a *therapeutic use |6 Q000627 | |
653 | 2 | |a COVID-19 |6 D000086382 |a complications |6 Q000150 |a *therapy |6 Q000628 | |
653 | 2 | |a *Extracorporeal Membrane Oxygenation |6 D015199 | |
653 | 2 | |a Humans |6 D006801 | |
653 | 2 | |a Male |6 D008297 | |
653 | 2 | |a Methylprednisolone |6 D008775 |a *therapeutic use |6 Q000627 | |
653 | 2 | |a Middle Aged |6 D008875 | |
653 | 2 | |a Pyrazines |6 D011719 |a *therapeutic use |6 Q000627 | |
653 | 2 | |a *Respiration, Artificial |6 D012121 | |
653 | 2 | |a Respiratory Insufficiency |6 D012131 |a therapy |6 Q000628 |a virology |6 Q000821 | |
653 | 2 | |a SARS-CoV-2 |6 D000086402 | |
655 | 7 | |a COVID-19 |2 gnd | |
655 | 7 | |a corticosteroid |2 gnd | |
655 | 7 | |a extracorporeal membrane oxygenation |2 gnd | |
655 | 7 | |a favipiravir |2 gnd | |
655 | 7 | |a mechanical ventilation |2 gnd | |
655 | 7 | |a Adrenal Cortex Hormones |2 gnd | |
655 | 7 | |a Amides |2 gnd | |
655 | 7 | |a Antiviral Agents |2 gnd | |
655 | 7 | |a Pyrazines |2 gnd | |
655 | 7 | |a favipiravir |2 gnd | |
655 | 7 | |a EW5GL2X7E0 |2 gnd | |
655 | 7 | |a Methylprednisolone |2 gnd | |
655 | 7 | |a X4W7ZR7023 |2 gnd | |
689 | 0 | 0 | |A f |a Case Reports |
689 | 0 | 1 | |A f |a Journal Article |
689 | 0 | |5 DE-601 | |
689 | 1 | 0 | |a COVID-19 |
689 | 1 | 1 | |a corticosteroid |
689 | 1 | 2 | |a extracorporeal membrane oxygenation |
689 | 1 | 3 | |a favipiravir |
689 | 1 | 4 | |a mechanical ventilation |
689 | 1 | |5 DE-601 | |
689 | 2 | 0 | |a Adrenal Cortex Hormones |
689 | 2 | 1 | |a Amides |
689 | 2 | 2 | |a Antiviral Agents |
689 | 2 | 3 | |a Pyrazines |
689 | 2 | 4 | |a favipiravir |
689 | 2 | 5 | |A r |a EW5GL2X7E0 |
689 | 2 | 6 | |a Methylprednisolone |
689 | 2 | 7 | |A r |a X4W7ZR7023 |
689 | 2 | |5 DE-601 | |
700 | 1 | |a Kamachi, Kenichi | |
700 | 1 | |a Ota, Shinichiro | |
700 | 1 | |a Yoshimatsu, Lynn | |
700 | 1 | |a Boku, Ryuichi | |
700 | 1 | |a Yoshida, Yuto | |
700 | 1 | |a Hirouchi, Takatomo | |
700 | 1 | |a Shinada, Kanako | |
700 | 1 | |a Sato, Takashi | |
700 | 1 | |a Morikawa, Miwa | |
700 | 1 | |a Iwata, Koki | |
700 | 1 | |a Matsumoto, Takashi | |
700 | 1 | |a Shinkai, Masaharu | |
773 | 0 | 8 | |i in |t Internal medicine (Tokyo, Japan) |g Vol. 60, No. 1 (2021), p. 123-130 |q 60:1<123-130 |w (DE-601)NLM012606820 |x 1349-7235 |
856 | 4 | 1 | |u http://dx.doi.org/10.2169/internalmedicine.5475-20 |3 Volltext |
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 60 |j 2021 |e 1 |b 31 |h 123-130 |